US FDA misses biosimilars guidance deadline
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration missed its 31 December 2011 goal of issuing three general guidance documents for companies intending to seek approval of biosimilars, although a spokeswoman suggested they might be issued in early January1.